Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees.

A large stock preparation of the HIV-1SF2 isolate has been derived after serial passage in human peripheral blood mononuclear cells (PBMCs). This viral stock has a titer of 10(4.9) TCID50 in human PBMCs and 10(4.2) TCID50 in chimpanzee PBMCs. By inoculation into animals the 50% chimpanzee infectious dose titer was found to be about 10(2.3). Virus isolation from animals was achieved on most occasions within 1-4 weeks after inoculation and then became transient. Viral RNA and DNA PCR analyses confirmed the virus infection of the chimpanzees. Anti-HIV antibody levels in the inoculated animals ranged from 1:400 to 1:6400 as measured by ELISA. About 680 vials of this stock preparation, frozen at -190 degrees C, are available for future studies of vaccines and antiviral therapies.

[1]  E. Singer,et al.  Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[2]  K. Steimer,et al.  Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV‐1SF2 , 1995, AIDS.

[3]  M. Kieny,et al.  Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 , 1995, Journal of virology.

[4]  R. Desrosiers,et al.  Titration and characterization of two rhesus-derived SIVmac challenge stocks. , 1994, AIDS research and human retroviruses.

[5]  M. Kieny,et al.  Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. , 1992, Science.

[6]  J. Levy,et al.  CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. , 1992, AIDS research and human retroviruses.

[7]  J. Mullins,et al.  Molecular Epidemiology of HIV Transmission in a Dental Practice , 1992, Science.

[8]  W. Schleif,et al.  Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.

[9]  K. Murthy,et al.  Prevention of HIV infection by passive immunization with HIV immunoglobulin. , 1991, AIDS research and human retroviruses.

[10]  J. Mordenti,et al.  Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin , 1991, Nature.

[11]  J. Levy,et al.  Rapid CD8+ Cell Anti-HIV Activity Correlates with the Clinical State of the Infected Individual , 2003 .

[12]  M. Kieny,et al.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[14]  T. Ryder,et al.  Rapid and quantitative detection of enzymatically amplified HIV-1 DNA using chemiluminescent oligonucleotide probes. , 1990, AIDS research and human retroviruses.

[15]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[16]  L. Arthur,et al.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120 , 1989, Journal of virology.

[17]  J. Levy,et al.  Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment. , 1989, AIDS research and human retroviruses.

[18]  R. Weiss,et al.  Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[20]  C. Cheng‐Mayer,et al.  Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Desrosiers,et al.  Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. , 1987, The Journal of general virology.

[22]  J. Levy,et al.  Differential ability of human immunodeficiency virus isolates to productively infect human cells. , 1987, Journal of immunology.

[23]  C. Cheng‐Mayer,et al.  Patterns of antibody response in individuals infected with the human immunodeficiency virus. , 1987, The Journal of infectious diseases.

[24]  R. B. Swenson,et al.  Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome , 1986, Journal of virology.

[25]  J. Levy,et al.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. , 1985, Virology.

[26]  W. Saxinger,et al.  Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. , 1984, Science.

[27]  J. Levy,et al.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. , 1984, Science.

[28]  T. Wrin,et al.  Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. , 1996, The Journal of infectious diseases.

[29]  J. Levy,et al.  Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees. , 1991, Cellular immunology.

[30]  D. Francis,et al.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). , 1985, Journal of immunological methods.